Fast Five Quiz: Joint Pain

Herbert S. Diamond, MD

Disclosures

February 12, 2019

According to ACR guidelines, in patients with early RA, if disease activity remains moderate or high despite use of a DMARD or biologic therapies, low-dose glucocorticoids should be added to the therapy regimen. If the disease flares, short-term glucocorticoids at the lowest possible dose for the shortest possible duration are recommended. In patients with early RA, if disease activity remains moderate or high despite DMARD use, TNFi monotherapy is recommended over tofacitinib monotherapy. In this group, a TNFi and MTX are recommended over tofacitinib and MTX.

If disease activity is low in patients with established RA who have never taken a DMARD, DMARD monotherapy is recommended over a TNFi. If disease activity is moderate or high in patients who have never taken a DMARD, DMARD monotherapy (MTX preferred) is recommended over tofacitinib. DMARD monotherapy is also preferred over combination DMARD therapy in this patient group.

Read more about the treatment of RA.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....